

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Spikevax (Moderna) in children aged 6 to 11 years, two-year health outcomes in hospitalised COVID-19 patients, coronavirus ‘ghosts’

Peer reviewed journals featured:

- A randomised controlled trial of Spikevax (Moderna) vaccine in children 6 – 11 years of age [here](#)
- Observational studies on:
 - Health outcomes in people two years after hospitalisation with COVID-19 [here](#)
 - Paediatric ICU admissions with deliberate self-harm during the SARS-CoV-2 outbreak in Australia [here](#)
 - Effect of mRNA boosters against Omicron infection in Qatar [here](#)
 - Neuropsychiatric impact of severe COVID-19 and other severe respiratory infections [here](#)
 - Serological response to Comirnaty (Pfizer) vaccination in patients with multiple sclerosis treated with rituximab [here](#)
 - Impaired immune responses in blood cancers improved by the third vaccine dose [here](#)
- A machine learning model to predict COVID-19 infection and severity risk in the UK [here](#)
- Commentary on:
 - The removal of mask mandates [here](#)
 - Exemptions to vaccine mandates [here](#) and [here](#)

Pre-peer review articles featured:

- The impact of side effect framing on COVID-19 booster vaccine intentions in Australian’s [here](#)
- BA.2 Omicron differs immunologically from both BA.1 Omicron and pre-Omicron variants [here](#)

News and blogs

- Coronavirus ‘ghosts’ found lingering in the gut [here](#)

[Click here](#) to subscribe to the daily evidence digest.